상세정보
- |Home >
- 상세정보
부가기능
Epizyme Builds A Cancer Company At Mach Speed: Epizyme's recent alliance with Celgene validates industry's interest in histone methyltransferase inhibitors, a kinase-like class of epigenetic enzymes. Celgene's willingness to cede US rights in return for access to preclinical assets belies HMTs' novelty and helps to position Epizyme for potential success as a US-focused oncology company. Despite the strong start, it won't be easy
기사 상세정보
소장정보
- 소장정보
| No. | 권호·제본정보 보기 | 소장처 | 소장사항 | 청구기호 | 구독 | 최근입수호 |
|---|---|---|---|---|---|---|
| 1 | 중앙도서관/3층 외국학술지지원센터/ | 610 I35 | 구독중단 | v.34 no.11 |
하단메뉴
